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Abnormal Hedgehog pathway in myelodysplastic 
syndrome and its impact on patients’ outcome 
Myelodysplastic syndromes (MDS) are clonal
hematopoietic stem cell disorders characterized by ineffec-
tive hematopoiesis and by cytopenias. Approximately
30% of patients with MDS progress to acute myeloid
leukemia.1 Thus, it is important to identify risk factors for
AML progression and to guide treatment decisions that
can have a positive impact on patient mortality. The
Hedgehog (Hh) pathway is an important mediator of early
hematopoietic development2 and, for the last two decades,
a number of studies have linked an abnormal Hh signaling
to distinct human malignancies.3 Previous evidence has
suggested that Hh signaling plays a role in hematopoietic
malignancies.4 Kobune et al. showed activation of Hh sig-
naling in primary CD34+ blasts from AML5 and, recently,
these same authors reported the expression of Indian Hh
(IHH) and Smoothed (SMO) in AML- and MDS-derived
CD34+ cells.6 Here, we characterize expression of central
components of the Hh pathway in the bone marrow (BM)
of MDS patients. Moreover, we investigated the impact of
the mRNA expression of these key elements on MDS out-
come and survival. 
Patients with diagnosis of de novoMDS (n=69), untreat-
ed at the time of sample collection, were included in the
study. Among these 69 patients, 63 had their BM collected
for mRNA, 49 had biopsies collected for immunohisto-
chemistry (IHQ) of whom 40 had both mRNA and IHQ.
Patients’ characteristics are described in Table 1. Nineteen
healthy donors and 7 patients with megaloblastic anemia
(MA) were analyzed as control; these had their BM collect-
ed for mRNA and protein expression analysis, respectively.
All subjects provided written informed consent and the
study was approved by the local Ethics Committee.
Analysis of comparison between groups was performed by
the Mann-Whitney method and co-variance (ANCOVA)
controlling for age, followed by post hoc comparisons using
the Tukey test, when applied. Univariate and multivariate
Cox regression were used to estimate overall survival (OS),
event-free survival,7 and AML evolution for MDS patients.
OS was defined as the time (in months) between the date
of sampling and the date of death (for deceased patients)
or last follow up (for censored patients). Event-free sur-
vival (EFS) was defined as the time (in months) between
the sampling and the date of the first event (death or MDS
progression to a higher risk MDS category by WHO or to
AML with myelodysplastic-related changes) or last follow
up (for censored patients). AML evolution was defined as
the time (in months) from the date of sampling to diagno-
sis of AML. Kaplan-Meier analysis, based on the gene
expression categorized as median, and log rank test were
used to construct survival curves. All tests were two-tailed
and P<0.05 was considered statistically significant.  
For protein expression analysis, the expression of Hh lig-
ands, Dessert Hh (DHH), Sonic Hh (SHH) and Indian Hh
(IHH) were compared in BM biopsies from MDS and from
megaloblastic anemia (MA) patients by immunohisto-
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Table 1. Patients’ characteristics.
Characteristics                                                          Value
Age (yr) at time of sampling; median (range)            65 (16-91)
Gender, n (%)                                                                              
Male/female                                                               42 (61) / 27 (39)
WHO 2008, n                                                                                  
RCUD/RCMD/RARS                                                           12/29/4
RAEB-1/RAEB-2                                                                   14/10
IPSS risk group, n                                                                        
Low/ Int-1                                                                              23/31
Int-2/High                                                                                8/3
Not available                                                                            4
WHO: World Health Organization; RCUD: refractory cytopenia with unilineage dys-
plasia; RCMD: refractory cytopenia with multilineage dysplasia; RARS: refractory ane-
mia with ringed sideroblasts; RAEB-1: refractory cytopenia with excess blasts – 1;
RAEB-2: refractory cytopenia with excess blasts – 2; IPSS: International Prognostic
Scoring System; Int: intermediate. 
Table 2. Univariate analyses of survival outcomes.
Factor Event-free survival Overall survival AML evolution
Hazard Ratio P Hazard Ratio P Hazard Ratio P
(95% CI) (95% CI) (95% CI)
Gender
Male vs. female 1.70 (0.80-3.60) 0.16 1.60 (0.75-3.41) 0.21 2.18 (0.71-6.66) 0.17
WHO 2008 classification*
RAEB-1/RAEB-2 vs.RCUD/RCMD/RARS 5.07 (2.43-10.59) <0.0001 5.85 (2.73-12.5) <0.0001 7.75 (2.33-25.7) 0.001
IPSS risk group*
Int-2 / High vs.
Int-1 /Low 5.53 (2.42-12.6) <0.0001 6.56 (2.85-15.0) <0.0001 4.63 (1.33-16.1) 0.01
Gene expression; continuous variable&
Age at sampling 1.00 (0.98-1.03) 0.51 1.00 (0.98-1.03) 0.63 0.99 (0.96-1.03) 0.81 
SMO expression# 1.009 (1.00-1.01) 0.02 1.00 (1.00-1.01) 0.04 1.01 (1.00-1.02) 0.00 3 
PTCH1 expression 1.02 (0.97-1.07) 0.44 1.00 (0.94-1.06) 0.95 1.05 (0.98-1.12) 0.13
SUFU expression 1.04 (0.90-1.19) 0.58 1.00 (0.86-1.17) 0.94 1.09 (0.91-1.31) 0.32 
GLI1 expression 1.09 (0.31-3.75) 0.89 0.18 (0.006-5.90) 0.33 0.41 (0.01-13.7) 0.62
GLI2 expression 2.46 (0.25-23.7) 0.43 3.40 (0.34-33.7) 0.29 2.00 (0.03-143.5) 0.75 
GLI3 expression 1.005 (0.99-1.02) 0.47 1.00 (0.99-1.02) 0.38 1.004 (0.98-1.02) 0.75
MDS: myelodysplastic syndromes; AML: acute myeloid leukemia; WHO: World Health Organization; RCUD: refractory cytopenia with unilineage dysplasia; RCMD: refractory
cytopenia with multilineage dysplasia; RARS: refractory anemia with ringed sideroblasts; RAEB-1: refractory cytopenia with excess blasts – 1; RAEB-2: refractory cytopenia with
excess blasts – 2; IPSS: International Prognostic Scoring System; Int: intermediate. *Hazard ratio >1 indicates that the first feature has the poorest outcome. #Higher SMO expres-
sion predicts poorest outcome. &The number of patients tested for each gene is indicated: SMO=62, PTCH1= 62, SUFU=57, GLI1=62, GLI2=52, GLI3=56.
chemistry. We chose MA as a control, as ineffective
hematopoiesis is a marker of both diseases although the
causes are different.8 Based on morphological aspects,
DHH was likely expressed in both erythroid and myeloid
precursors and SHH predominated in erythroid precursors,
as positive cells were arranged in a nest (Figure 1A). DHH
and SHH expressions were significantly higher in the MDS
group (P=0.0002 and P<0.0001, respectively) (Figure 1B
and C). There was no statistical difference between the
MDS and the MA groups for IHH expression (Online
Supplementary Figure S1A). Hh ligand protein expression
did not predict either EFS nor OS (all P>0.05). There was
no correlation of percentage of blasts with Hh ligand
expression level (data not shown). Few studies have shown
the deregulation of Hh signaling in the BM of hematologic
malignancies by immunohistochemistry; high SHH pro-
tein levels, for example, have been described in the BM
samples of patients with acute promyelocytic leukemia,
AML and multiple myeloma.9,10 This is the first time, to our
knowledge, that an increase in Hh ligands has been
described in the BM of MDS. 
Subsequently, we used quantitative polymerase chain
reaction (qPCR) to analyze the mRNA expression of mol-
ecules belonging to the Hh pathway in total BM cells from
healthy donors and MDS patients. There was no statistical
difference in SMO expression levels between control and
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Figure 1. Hedgehog pathway is deregulated
in MDS total bone marrow. (A)
Immunohistochemical expression of DHH
(upper panel) and SHH (lower panel) in bone
marrow biopsies from MDS, and from mega-
loblastic anemia (MA) patients. Both anti-
bodies were purchased from Santa Cruz and
diluted at 1:50 in citrate buffer. Green and
black arrows indicate likely erythroblasts
and myeloid precursors, respectively. Graph
shows quantitative analysis of IHQ, where
four random high-powered fields from
stained slides were captured at 20x objec-
tive magnification and visualized for manual
scoring for positive cells, using ImageJ
(http://imagej.nih.gov/ij/). Horizontal lines
indicate medians of positive cells for DHH (B)
and SHH (C). Quantitative PCR analysis of
SMOmRNA expression in (D) total bone mar-
row cells from healthy donors and from
patients with MDS and (E) stratified accord-
ing to the WHO 2008 classification.
Expression of HPRT transcripts was used as
an endogenous control. The relative gene
expression was calculated using the equa-
tion 2−ΔΔCT 11. Horizontal lines indicate medi-
ans. Mann-Whitney test was used for com-
parisons between two groups (control vs.
MDS). ANCOVA followed by post hoc Tukey
was used for comparisons among control,
RAEB-1/RAEB-2 and RCUD/RCMD/RARS
groups. The numbers of individuals and 
P values are indicated in the graphs. Event-
free survival (F) and freedom from AML evo-
lution (G) of MDS patients categorized as
median of SMO expression levels (Kaplan-
Meier curves). Patients were subgrouped by
high SMO expression (above median; 1.74)
and low SMO expression (below median). 
P values are indicated in the graph (log rank
test). 
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the MDS group (Figure 1D). Nevertheless, when MDS
samples were classified, according to WHO 2008, we
observed a significant increase of age-adjusted expression
of SMO in the group of patients with RAEB-1 and RAEB-
2 when compared to the control and to 5% or less BM
blast MDS patients (RCUD, RCMD and RARS) (P=0.005
and P=0.008, respectively) (Figure 1E). There was no sig-
nificant difference in age-adjusted expression of Patched1
(PTCH1), Suppressor of fused protein (SUFU), GLI1, GL2 and
GLI3 transcripts between MDS patients and healthy
donors (Online Supplementary Figure S1B-F). Consistent
with these findings, high expression of SMO has been
reported in human colonic tumors.12 Recently, experimen-
tal data have shown that SMO was significantly increased
in a mouse model for familial adenomatous polyposis. The
authors also mentioned that SMO expression was
increased in 9 of 20 cancer samples compared with the
normal epithelium of the same patients. Unexpectedly, in
that study, reduced expression of SMO did not suppress
GLI-dependent Hh signaling in intestinal tumor cells, sug-
gesting that SMO could contribute to the proliferation of
those cells by a mechanism independent of GLI-mediated
transcription.13 
In our study, Kaplan-Meier analysis indicated a 5-year
EFS of 31% versus 53% for patients with higher SMO
expression (above median) versus lower SMO expression,
respectively (P=0.04) (Figure 1F). The same was observed
for 5-year AML evolution (49%>1.74 SMO vs. 91% <1.74
SMO; P=0.002) (Figure 1G). Univariate analysis showed
that WHO diagnosis of RAEB-1 and RAEB-2, IPSS inter-
mediate-2 and high risk, together with increased SMO
expression (continuous variable) predicted worse EFS, OS
and AML evolution (Table 2). As expected, the usual prog-
nostic factors, including WHO 2008 classification and
IPSS, remained independent predictors for EFS, OS, AML
evolution, and for EFS and OS, respectively (Online
Supplementary Table S1). Our findings corroborate other
studies that have identified SMO overexpression as being
significantly associated with poor prognosis of hepatoblas-
toma,14 malignant pleural mesothelioma,15 and also as an
independent prognostic factor for post-operative liver
metastasis-free survival in colon cancer.16 Recently, SMO
expression was reported to induce fatal AML in a mouse
model of MDS, resulting in a reduced survival and wide-
spread expansion of immature myeloid cells.17 Taken
together, it seems reasonable to suggest that alterations in
the Hh pathway might be involved in MDS progression;
however, whether this mechanism is dependent or not on
the canonical Hh pathway requires further investigation. 
Hedgehog signaling has gained interest as a prognostic
marker and as a potential therapeutic strategy in a range of
cancers.4 Here, we describe an abnormal Hh signaling
pathway in total BM cell from MDS patients and the pos-
sible involvement of SMO in MDS progression. 
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